Specialty drug costs employer plans face can be difficult to predict because a small number of complex therapies may account for a concentrated share of pharmacy spending. For Washington employers, the right response is not to treat every high-cost prescription as a problem to restrict. It is to understand what is driving the expense, establish clear oversight, and protect employees’ access to appropriate care while making plan decisions that fit the organization’s budget and values.
Book a conversation about your employee benefits strategy
Why Do Specialty Drug Costs Matter to Employer Health Plans?
Specialty medications are often used to treat complex or chronic conditions and may involve special handling, monitoring, or support. They can be expensive, and the cost of one treatment may have a noticeable effect on a plan’s claims experience. Research on specialty pharmacy describes these medications as a major challenge in employer benefit purchasing, while other published work has examined how employers respond to their rising costs. A review of employer specialty-drug management and research on employer responses to specialty-drug costs provide useful background.
The issue is not only the amount paid for a drug. A plan’s total exposure can depend on how a medication is covered, where it is dispensed or administered, how claims are processed, what clinical requirements apply, and how the member’s cost share is designed. Employer leaders may see a large claim or a renewal increase without having enough detail to tell which factors contributed. That uncertainty can make it hard to distinguish an isolated high-cost event from a pattern that calls for a broader review.
Specialty-drug decisions also sit at the intersection of employee health, plan design, contract terms, and financial forecasting. A policy that appears to control spending on paper may create confusion or delay if employees and clinicians do not understand how it works. Conversely, a benefit that provides access without meaningful oversight may leave the employer with unanswered questions about value and predictability. Good governance makes those tradeoffs visible before renewal, not after a difficult claim has become a crisis.
Employers do not need to make clinical decisions. They do need to ask their advisor and pharmacy partners for clear explanations of plan operations, reporting, financial responsibilities, and member support. This article focuses on those employer-level questions, rather than advice about whether an individual should take or change a medication.
Which Factors Can Drive Specialty Drug Spending?
There is rarely one explanation for a plan’s specialty-drug spending. A useful review separates the factors into categories so the employer can ask the right partner for the information and avoid drawing conclusions from a headline total alone.
- Utilization and clinical mix: The number of members using specialty therapies, the conditions being treated, and changes in treatment patterns can affect claims from one period to another. Employers should review aggregate trends with appropriate privacy protections, not seek identifiable medical details.
- Drug price and coverage terms: The plan’s allowed amounts, formulary placement, rebate arrangements, and contract definitions can influence reported net and gross costs. Employers should clarify which figures they are seeing and what is or is not included.
- Pharmacy channel and dispensing arrangements: A medication may be obtained through a specialty pharmacy or another approved channel, depending on the plan and drug. The arrangement can affect service, billing, and the way claims appear in reports.
- Site of care and administration: Some medications are self-administered; others may be administered in a clinical setting. The plan’s coverage rules and the setting used can affect the overall claim. Any care decision belongs with the member and their clinician.
- Member cost sharing and assistance: Deductibles, coinsurance, copayments, and applicable assistance programs shape what the plan and member pay. Employers should ask how the plan calculates member responsibility and how changes could affect access.
- One-time or high-impact claims: A small number of large claims can make year-over-year comparisons volatile. A report should explain whether a trend reflects recurring use, a change in utilization, or a limited number of high-cost events.
These factors can interact. For example, a change in the number of members using a therapy may coincide with a plan-year change in coverage or reporting. A single total cannot tell the employer whether the cause is utilization, unit price, contract terms, or a combination. Ask for a description of the methodology behind each report and a plain-language explanation of what changed.
What Should Employers Ask Their Pharmacy and Benefits Partners?
Employers can begin with a practical review meeting that brings together the benefits advisor, pharmacy benefits partner, plan administrator, and the people responsible for the budget and employee communications. The aim is to agree on a reliable picture of the plan, not to debate an unexplained spreadsheet.
- How is “specialty” defined? Ask which products or claims are included in the category, and whether the definition changes by report, contract, or benefit channel. A consistent definition is necessary for meaningful year-over-year comparison.
- What time period and population does the report cover? Confirm the paid-through date, whether claims are run-out adjusted, and whether the report compares equivalent periods. Clarify how eligibility changes and plan design changes are handled.
- Which costs are gross, net, plan-paid, or member-paid? Request separate definitions for amounts billed, allowed amounts, plan payments, member cost sharing, rebates, and other adjustments. Do not assume that a summary figure represents the final net cost.
- What changed from the prior period? Ask partners to identify whether the change appears related to member count, utilization, drug mix, unit cost, site of care, or plan terms. They should also state what the data cannot establish.
- How do coverage rules work in practice? Request a clear explanation of prior authorization, step therapy, specialty pharmacy requirements, exceptions, appeals, and who helps members navigate them. Employers should understand the process and safeguards without attempting to direct an individual’s treatment.
- What does an employee experience? Ask how members learn where to obtain a medication, whom to call with a coverage question, how continuity is handled during a transition, and what happens when a claim is delayed or denied.
- Who is accountable for each action? Document which partner owns reporting, clinical review, authorizations, appeals, member outreach, claims corrections, and escalation. A named role or team is more useful than a general promise of support.
Employer reporting should protect confidentiality. Ask for aggregated data, minimum cell-size rules where applicable, and a description of how sensitive information is handled. Avoid requesting member names or diagnoses in a routine finance review. When a case-specific question arises, follow the plan’s established privacy and administration channels.
How Can Employers Compare the Main Oversight Options?
There is no single design choice that fits every employer. Each option has operational requirements and tradeoffs. The table below is a discussion framework for evaluating proposals with qualified partners; it is not a recommendation to change a member’s care or a substitute for reviewing the actual plan documents and contracts.
| Approach to review | What it can help clarify | Questions and tradeoffs for the employer |
|---|---|---|
| Improve reporting and contract visibility | Definitions, claim timing, gross and net amounts, and the roles of each pharmacy partner. | Can the partner provide consistent reports and explain fees, adjustments, and limitations? What data is available at renewal and during the year? |
| Review formulary and utilization-management processes | How coverage criteria, prior authorization, exceptions, and appeals are administered. | Who makes clinical determinations? How are rules communicated, reviewed, and appealed? What support is available to members and prescribers? |
| Assess pharmacy and site-of-care arrangements | Where eligible medications are dispensed or administered and how those channels are coordinated. | What does the contract permit? How are access, continuity, convenience, billing, and clinical appropriateness considered? |
| Evaluate plan cost-sharing design | How the plan and member share covered costs under the written benefit. | What would a proposed change mean for employee affordability and access? Are plan documents, notices, and payroll administration aligned? |
| Establish ongoing governance | Who reviews trends, escalates service issues, and tracks agreed actions across the year. | Are responsibilities, privacy safeguards, review dates, and success measures documented? Can HR manage the process without adding unnecessary burden? |
Consider the options as a sequence rather than a menu of quick fixes. First establish reliable definitions and a baseline. Then determine whether a particular process or contract term warrants review. Finally, assess any proposed design change for its effect on employees, administration, and the plan budget. A change should not be treated as successful solely because one line item falls; the employer should also understand service quality, access, and the full financial picture.
How Can Employers Evaluate a Proposed Change Before Renewal?
Ask the partner presenting a change to explain the current-state problem, the specific mechanism the proposal would change, and the evidence that supports the recommendation. A statement such as “this will control specialty costs” is not enough to make a decision. Employers should be able to see which contract term or workflow changes, how the change is expected to affect claims or administration, and what assumptions could make the result differ from the projection.
Separate a forecast from an observed result. A projection may rely on historical claims, anticipated enrollment, negotiated terms, or assumptions about future utilization. Ask what period it covers, whether it uses the employer’s own experience, and which costs it includes. If a proposed arrangement depends on a particular pharmacy channel or utilization process, confirm that the operational steps and member communications are ready before treating the projected outcome as achievable.
Use a written comparison that considers both financial and service measures. Examples include consistency of reporting, time to resolve a coverage question, clarity of the appeal route, implementation work for HR, and the employer’s ability to reconcile invoices and reports. These are not substitutes for a financial analysis; they help identify whether the proposal is workable and whether its intended safeguards are in place. Assign a person to verify each measure rather than assuming that a partner will report it automatically.
Finally, agree in advance how the employer will revisit the decision. Record the baseline, the expected change, the evidence source, the person responsible for follow-up, and a review date. If the actual experience differs from the projection, ask why before extending or expanding the arrangement. This creates a learning process for future renewals and helps prevent a one-time estimate from being mistaken for a guaranteed outcome.
Employers managing other plan structures can use a similar decision discipline. For example, a discussion of how level-funded plans work may help leaders frame broader questions about claims volatility and risk, while remaining distinct from the specific pharmacy terms that determine specialty-drug coverage.
How Should Washington Employers Build a Specialty-Drug Governance Process?
A governance process does not need to be complicated. It needs a predictable calendar, defined owners, useful information, and a way to follow through. Smaller Washington employers may not have a dedicated pharmacy team, so the broker and plan partners should make the process understandable and manageable.
1. Set the review team and objectives
Identify a business owner for the review, often an HR or finance leader, and invite the benefits advisor and relevant plan partners. Agree on the questions the team needs answered: What is driving the trend? Are reports consistent? Are employees receiving clear support? Which contract or plan decisions require action before renewal? Keep the scope focused on plan governance, not individual treatment decisions.
2. Establish a baseline before comparing solutions
Gather comparable reports for consistent periods and ask partners to explain definitions, dates, adjustments, and any changes in the covered population or plan. Record what is known, what is estimated, and what cannot be measured. If the data is incomplete, make obtaining better information an action item rather than presenting an uncertain estimate as fact.
3. Map the member journey and escalation path
Write down how an employee or prescriber moves from a prescription to coverage determination, dispensing or administration, and follow-up support. Identify the contact point for questions, appeals, and urgent service problems. Ask the partners how they coordinate when a member changes plans or encounters a disruption. Test the process from an employee’s perspective without using a real member’s protected information.
4. Review plan and contract language with the right specialists
Before changing a benefit, have the appropriate plan, legal, clinical, and compliance professionals review the relevant documents and requirements. Verify that the proposed rule is supported by the contract, can be administered as intended, and has a workable exception and appeal process. Employers should not rely on a slide presentation or verbal summary as a substitute for the controlling documents.
5. Compare proposals on more than a quoted price
Ask each partner to explain assumptions, implementation needs, service responsibilities, reporting, and potential effects on employee experience. Check whether a proposal shifts costs between the medical and pharmacy benefit or between the plan and members rather than reducing the overall burden. If a proposal depends on a rebate or other adjustment, clarify its timing, eligibility, and treatment in the financial analysis.
6. Communicate clearly and review after implementation
If plan terms change, provide employees with timely, plain-language information about what is changing, where to ask questions, and how to use the established support channels. After implementation, review whether administration matched the intended design, whether reporting remains comparable, and whether service concerns surfaced. A renewal decision should use those findings, not just an initial projection.
For Washington employers reviewing the larger benefits picture, the agency’s guides to large-group health plans and small-group coverage can provide additional context about the employer market. The appropriate questions will vary with group size, plan arrangement, and internal capacity.
How Can Employers Balance Cost Oversight With Employee Support?
Cost management and access are not opposing goals. A well-governed plan can scrutinize pricing and administration while giving employees a clear path to understand their benefits. Employers should make sure that any proposed control is evaluated for how it works in real situations, including exceptions, appeals, continuity, and timely communication.
Useful employee support is specific. Instead of telling a member to “call the pharmacy,” provide the correct plan contact and explain what information to have available. Make sure HR knows where to direct a question without collecting unnecessary medical details. Ask the administrator how unresolved issues are escalated, what response expectations apply, and how the employer receives a de-identified summary of recurring service problems.
Employers can also review whether the plan’s written materials and onboarding explain the difference between the medical and pharmacy benefits, how specialty prescriptions are handled, and where members can seek help. A clear communication plan can reduce avoidable confusion, but it cannot guarantee coverage or replace a clinician’s advice. Members should discuss treatment choices with their health professionals and use the plan’s formal channels for coverage questions.
For additional employer-level context, published research on how employers have approached specialty-drug costs describes cost management as a benefits and purchasing challenge. A separate academic analysis of specialty drugs and health care costs offers broader context on why these therapies draw policy attention. These sources do not determine which design is right for a particular Washington employer; the plan’s data, documents, workforce needs, and professional guidance matter.
Benefits leaders should treat claims and employee feedback as complementary signals. Claims analysis can reveal patterns but may not explain the experience behind them. Employee questions can identify communication or navigation problems but do not, by themselves, establish the financial cause of a trend. Bring both into a structured review, while keeping personal health information private and limiting access to those who need it for plan administration.
What Should Employers Bring to a Renewal Review?
Before a renewal meeting, prepare a short decision file so the conversation produces clear next steps. Include the current plan and relevant pharmacy contract documents, comparable claims reports, a list of known data limitations, and a summary of recurring service concerns without identifying employees. Ask the advisor or administrator to flag any impending decision dates that affect implementation or required notices.
- Confirm that specialty-drug definitions and reporting periods match across the materials.
- Request a plain-language explanation of the largest observed changes and the assumptions behind any projection.
- Separate plan-paid, member-paid, gross, net, and adjusted figures instead of relying on one blended number.
- Review the administration and employee-support impact of each proposal, including appeals and exceptions.
- Document the decision owner, required approvals, implementation steps, and date for a follow-up review.
Ask the advisor to distinguish documented findings from estimates and recommendations. Where a decision depends on missing information, assign someone to obtain it and set a date to revisit the choice. Employers can also compare the specialty-drug discussion with the wider plan review process described in the agency’s guide to comparing health plan out-of-pocket costs, while remembering that drug coverage and medical-plan cost sharing may involve different provisions.
Frequently Asked Questions
Are specialty medications always covered under the pharmacy benefit?
No universal rule applies to every plan or medication. Coverage and administration depend on the plan documents and the arrangement for a particular drug. Ask the administrator to explain whether a claim falls under the pharmacy benefit, medical benefit, or another defined process, and where members should direct questions.
Should an employer set a cap on specialty-drug coverage?
A cap can have significant coverage, affordability, legal, and employee-relations implications. Employers should not adopt one based only on a budget target or a general example from another organization. Have qualified benefits, legal, and clinical professionals review the plan terms and consequences, including required notices and available safeguards, before considering any change.
Can a specialty-drug report show exactly why costs changed?
Not always. Reports differ in definitions, timing, adjustments, and the detail they include. Ask the pharmacy partner to explain its methodology, separate utilization and cost components where possible, and identify limitations. A trend report is an input to investigation, not proof of a single cause.
What should HR do when an employee has a problem accessing a medication?
Direct the employee to the plan’s designated member-support or appeals channel and follow the employer’s established escalation process. HR should avoid making clinical judgments or collecting more personal health information than necessary. Ask the administrator how urgent concerns are routed and how recurring, de-identified issues are reported to the employer.
How often should employers review specialty-drug spending?
Set a cadence that matches the plan’s reporting and renewal calendar, and confirm with the plan partners what data is available between renewals. A periodic review can help identify questions earlier, while a renewal review can support decisions about contracts and plan design. The schedule should be practical for the employer and consistent with privacy and reporting safeguards.
Ready to Review Your Benefits Strategy?
Specialty-drug oversight works best when employers understand the data, know who is accountable, and consider both the financial and employee experience before changing plan rules. Washington Health Insurance Agency (WHIA) works with Washington employers on benefits strategy and plan review; the first step is a conversation about your organization’s questions and priorities.
Schedule a conversation about your health benefits
Bring your current reports and the questions you want answered, and ask your benefits partners to make the assumptions and next steps clear.